Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06780930
PHASE3

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Sponsor: Servier

View on ClinicalTrials.gov

Summary

The objective of this study is to determine the efficacy, safety, and pharmacokinetics of vorasidenib in Asian participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation. The study will begin with a safety lead-in (SLI) phase and then will transition to a randomized double-blind placebo-controlled phase. During the study participants will have study visits on day 1 and 15 of the first two cycles, and then only on day 1 of treatment cycles in the frequency included in the study schedule of assessments. All participants will have an end of treatment visit within 7 days after their last dose of study treatment. Approximately 28 (+5) days after treatment has ended, a safety follow-up visit will occur. Study visits may include questionnaires, blood tests, ECG, vital signs, and a physical examination. Beginning at the end of treatment visit participants will be contacted by phone every 6 months for overall survival up to 5 years after the last participant is randomized or until death, withdrawal of consent from overall study participation, lost to follow-up, or sponsor ending the study, whichever occurs first.

Official title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo- Controlled Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Key Details

Gender

All

Age Range

12 Years - Any

Study Type

INTERVENTIONAL

Enrollment

57

Start Date

2024-10-18

Completion Date

2030-10-31

Last Updated

2026-01-09

Healthy Volunteers

No

Interventions

DRUG

Vorasidenib

For oral administration once daily

DRUG

Placebo

For oral administration once daily

Locations (8)

The Second People's Hospital of Shenzhen

Shenzhen, Guangdong, China

West China Hospital Sichuan University

Chengdu, Sichuan, China

Tiantan Hospital

Beijing, China

Sanbo Brain Hospital, Capital Medical University

Beijing, China

Huashan Hospital Fudan University

Shanghai, China

The Second Affiliated Hospital of Air Force Military Medical University

Xi'an, China

Taipei Veterans General Hospital

Taipei, Taiwan

Chang Gung Memorial Hospital,

Taoyuan District, Taiwan